- Home
- KC vs AAPG Comparison
KC vs AAPG Comparison
Compare KC & AAPG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | KC | AAPG |
|---|---|---|
| Founded | 2012 | 2009 |
| Country | China | China |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.3B | 2.8B |
| IPO Year | 2020 | 2025 |
Fundamental Metrics
Financial Performance| Metric | KC | AAPG |
|---|---|---|
| Price | $10.88 | $30.35 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 5 |
| Target Price | $15.83 | ★ $48.50 |
| AVG Volume (30 Days) | ★ 1.7M | 4.1K |
| Earning Date | 11-19-2025 | 11-19-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $1,268,313,014.00 | $54,524,554.00 |
| Revenue This Year | $25.92 | N/A |
| Revenue Next Year | $17.44 | $368.64 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 24.11 | N/A |
| 52 Week Low | $8.06 | $16.50 |
| 52 Week High | $22.26 | $48.45 |
Technical Indicators
Market Signals| Indicator | KC | AAPG |
|---|---|---|
| Relative Strength Index (RSI) | 34.51 | 42.17 |
| Support Level | $11.15 | $28.50 |
| Resistance Level | $11.77 | $32.96 |
| Average True Range (ATR) | 0.43 | 0.70 |
| MACD | -0.06 | -0.05 |
| Stochastic Oscillator | 4.15 | 40.31 |
Price Performance
Historical ComparisonAbout KC Kingsoft Cloud Holdings Limited
Kingsoft Cloud Holdings Ltd is an independent cloud service provider in China. It provides integrated cloud-based services including cloud computing, storage, and delivery. Its products and services are Security, Database, Data Analysis, Networking, and others. Its solutions are medical, government affairs, finance, media, education, gaming, Vehicle solutions, and others.
About AAPG Ascentage Pharma Group International American Depository Shares
Ascentage Pharma Group International is a clinical-stage biotechnology company engaged in the development and sales of novel small-scale therapies for cancers, hepatitis B virus, or HBV, and certain age-related diseases. It focuses on developing therapies that inhibit protein-protein interactions to restore apoptosis or programmed cell death. The Group has one reportable operating segment, which is discovering, developing, and commercializing therapies to address medical needs in hematological malignancies. The company's geographical segments include the United States and Mainland China.